Neurocrine Biosciences (FRA:NB3) Inventory Turnover: 0.21 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NB3 Neurocrine Biosciences Inc FRA:NB3
94 GF Score
Price €152.20
GF Value €165.56
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Neurocrine Biosciences Inventory Turnover?

Neurocrine Biosciences FRA:NB3 -2.56% 94 Inventory Turnover is 0.21 as of Mar. 2026. GuruFocus rates FRA:NB3 with a GF Score™ of 94/100 and a GF Value™ of €165.56 (Fairly Valued). The stock has 6 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Neurocrine Biosciences's Cost of Goods Sold for the three months ended in Mar. 2026 was €12 Mil. Neurocrine Biosciences's Average Total Inventories for the quarter that ended in Mar. 2026 was €57 Mil. Neurocrine Biosciences's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.21.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Neurocrine Biosciences's Days Inventory for the three months ended in Mar. 2026 was 438.47.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Neurocrine Biosciences's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.08.

Neurocrine Biosciences  (FRA:NB3) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Neurocrine Biosciences's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory =Average Total Inventories (Q: Mar. 2026 )/Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=57.359/11.937*365 / 4
=438.47

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Neurocrine Biosciences's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=57.359 / 704.542
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Neurocrine Biosciences Inventory Turnover Related Terms

Neurocrine Biosciences Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Neurocrine Biosciences's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences Inventory Turnover Chart

Neurocrine Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.51 0.73 1.07 0.72 0.78

Neurocrine Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.19 0.22 0.25 0.21
FRA:NB3
94GF Score
Neurocrine Biosciences Inc FRA:NB3
Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurocrine Biosciences Inventory Turnover Calculation

Neurocrine Biosciences's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Inventory Turnover (A: Dec. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2025 ) / ((Total Inventories (A: Dec. 2024 ) + Total Inventories (A: Dec. 2025 )) / count )
=44.493 / ((54.817 + 58.926) / 2 )
=44.493 / 56.8715
=0.78

Neurocrine Biosciences's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover (Q: Mar. 2026 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Mar. 2026 ) / ((Total Inventories (Q: Dec. 2025 ) + Total Inventories (Q: Mar. 2026 )) / count )
=11.937 / ((58.926 + 55.792) / 2 )
=11.937 / 57.359
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Inventory Turnover →
What does a Inventory Turnover of 0.21 mean?
Neurocrine Biosciences (FRA:NB3) has a Inventory Turnover of 0.21 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Neurocrine Biosciences and its competitors.
Is Neurocrine Biosciences' Inventory Turnover too high?
Neurocrine Biosciences' current Inventory Turnover is 0.21. Overall, Neurocrine Biosciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Inventory Turnover compare to VTRS and ELAN?
Neurocrine Biosciences' Inventory Turnover of 0.21 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Drug Manufacturers company?
A good Inventory Turnover depends on the Drug Manufacturers industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Neurocrine Biosciences and its competitors. Neurocrine Biosciences's current Inventory Turnover is 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Fairly Valued. The stock's GF Value™ is €165.56, compared to a current price of €152.20 — trading 8.1% below its estimated fair value. The current Inventory Turnover is 0.21. Neurocrine Biosciences' overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current Inventory Turnover is 0.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of €152.20 is trading 8.1% below its estimated GF Value™ of €165.56. GuruFocus considers Neurocrine Biosciences to be Fairly Valued.

Key valuation signals for FRA:NB3:

  • Inventory Turnover: 0.21
  • GF Value™: €165.56 vs. price of €152.20 (8.1% below fair value)
  • GF Score™: 94/100 with 6 warning signs

No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
94GF Score

Get the complete analysis for FRA:NB3

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€152.20
Price
€165.56
GF Value